Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting

Se Won Oh, Ho Jun Chin, Dong Wan Chae, Ki Young Na

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Previous studies reported the beneficial effect of erythropoietin (EPO) in acute injuries. We followed patients with and without acute kidney injury (AKI) after coronary artery bypass grafting (CABG) and evaluated the effect of EPO on long-term outcome. We also assessed the efficacy of urinary neutrophil gelatinase-associated lipocalin (uNGAL) as a predictive marker of AKI. Seventy-one patients scheduled for elective CABG were randomly given either 300 U/kg of EPO or saline before CABG. The primary outcome was AKI, and the secondary outcome was the all-cause-mortality and composite of all-cause-mortality and end stage renal disease (ESRD). Twenty-one patients had AKI, 14 (66.7%) in the placebo group and 7 (33.3%) in the EPO group (P = 0.05). Also, uNGAL was higher in the patients with AKI than in those without AKI at baseline, 2, 4, 24, and 72 hr after CABG (P = 0.011). Among patients with AKI, 2-week creatinine (Cr) was not different from baseline Cr in the EPO group, but 2-week Cr was significantly higher than baseline Cr in the placebo group (P = 0.009). All-cause-mortality (P = 0.022) and the composite of all-cause-mortality and ESRD (P = 0.003) were reduced by EPO. EPO reduces all-cause-mortality and ESRD in patients with AKI, largely due to the beneficial effect of EPO on recovery after AKI.

Original languageEnglish
Pages (from-to)506-511
Number of pages6
JournalJournal of Korean Medical Science
Volume27
Issue number5
DOIs
Publication statusPublished - 2012 May 1
Externally publishedYes

Fingerprint

Erythropoietin
Acute Kidney Injury
Coronary Artery Bypass
Creatinine
Mortality
Chronic Kidney Failure
Placebos
Wounds and Injuries

Keywords

  • Erythropoietin
  • Mortality
  • Neutrophil gelatinase-associated lipocalin protein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. / Oh, Se Won; Chin, Ho Jun; Chae, Dong Wan; Na, Ki Young.

In: Journal of Korean Medical Science, Vol. 27, No. 5, 01.05.2012, p. 506-511.

Research output: Contribution to journalArticle

@article{e31c90a107074fa9b8c1a06fe48222e7,
title = "Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting",
abstract = "Previous studies reported the beneficial effect of erythropoietin (EPO) in acute injuries. We followed patients with and without acute kidney injury (AKI) after coronary artery bypass grafting (CABG) and evaluated the effect of EPO on long-term outcome. We also assessed the efficacy of urinary neutrophil gelatinase-associated lipocalin (uNGAL) as a predictive marker of AKI. Seventy-one patients scheduled for elective CABG were randomly given either 300 U/kg of EPO or saline before CABG. The primary outcome was AKI, and the secondary outcome was the all-cause-mortality and composite of all-cause-mortality and end stage renal disease (ESRD). Twenty-one patients had AKI, 14 (66.7{\%}) in the placebo group and 7 (33.3{\%}) in the EPO group (P = 0.05). Also, uNGAL was higher in the patients with AKI than in those without AKI at baseline, 2, 4, 24, and 72 hr after CABG (P = 0.011). Among patients with AKI, 2-week creatinine (Cr) was not different from baseline Cr in the EPO group, but 2-week Cr was significantly higher than baseline Cr in the placebo group (P = 0.009). All-cause-mortality (P = 0.022) and the composite of all-cause-mortality and ESRD (P = 0.003) were reduced by EPO. EPO reduces all-cause-mortality and ESRD in patients with AKI, largely due to the beneficial effect of EPO on recovery after AKI.",
keywords = "Erythropoietin, Mortality, Neutrophil gelatinase-associated lipocalin protein",
author = "Oh, {Se Won} and Chin, {Ho Jun} and Chae, {Dong Wan} and Na, {Ki Young}",
year = "2012",
month = "5",
day = "1",
doi = "10.3346/jkms.2012.27.5.506",
language = "English",
volume = "27",
pages = "506--511",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "5",

}

TY - JOUR

T1 - Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting

AU - Oh, Se Won

AU - Chin, Ho Jun

AU - Chae, Dong Wan

AU - Na, Ki Young

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Previous studies reported the beneficial effect of erythropoietin (EPO) in acute injuries. We followed patients with and without acute kidney injury (AKI) after coronary artery bypass grafting (CABG) and evaluated the effect of EPO on long-term outcome. We also assessed the efficacy of urinary neutrophil gelatinase-associated lipocalin (uNGAL) as a predictive marker of AKI. Seventy-one patients scheduled for elective CABG were randomly given either 300 U/kg of EPO or saline before CABG. The primary outcome was AKI, and the secondary outcome was the all-cause-mortality and composite of all-cause-mortality and end stage renal disease (ESRD). Twenty-one patients had AKI, 14 (66.7%) in the placebo group and 7 (33.3%) in the EPO group (P = 0.05). Also, uNGAL was higher in the patients with AKI than in those without AKI at baseline, 2, 4, 24, and 72 hr after CABG (P = 0.011). Among patients with AKI, 2-week creatinine (Cr) was not different from baseline Cr in the EPO group, but 2-week Cr was significantly higher than baseline Cr in the placebo group (P = 0.009). All-cause-mortality (P = 0.022) and the composite of all-cause-mortality and ESRD (P = 0.003) were reduced by EPO. EPO reduces all-cause-mortality and ESRD in patients with AKI, largely due to the beneficial effect of EPO on recovery after AKI.

AB - Previous studies reported the beneficial effect of erythropoietin (EPO) in acute injuries. We followed patients with and without acute kidney injury (AKI) after coronary artery bypass grafting (CABG) and evaluated the effect of EPO on long-term outcome. We also assessed the efficacy of urinary neutrophil gelatinase-associated lipocalin (uNGAL) as a predictive marker of AKI. Seventy-one patients scheduled for elective CABG were randomly given either 300 U/kg of EPO or saline before CABG. The primary outcome was AKI, and the secondary outcome was the all-cause-mortality and composite of all-cause-mortality and end stage renal disease (ESRD). Twenty-one patients had AKI, 14 (66.7%) in the placebo group and 7 (33.3%) in the EPO group (P = 0.05). Also, uNGAL was higher in the patients with AKI than in those without AKI at baseline, 2, 4, 24, and 72 hr after CABG (P = 0.011). Among patients with AKI, 2-week creatinine (Cr) was not different from baseline Cr in the EPO group, but 2-week Cr was significantly higher than baseline Cr in the placebo group (P = 0.009). All-cause-mortality (P = 0.022) and the composite of all-cause-mortality and ESRD (P = 0.003) were reduced by EPO. EPO reduces all-cause-mortality and ESRD in patients with AKI, largely due to the beneficial effect of EPO on recovery after AKI.

KW - Erythropoietin

KW - Mortality

KW - Neutrophil gelatinase-associated lipocalin protein

UR - http://www.scopus.com/inward/record.url?scp=84862860388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862860388&partnerID=8YFLogxK

U2 - 10.3346/jkms.2012.27.5.506

DO - 10.3346/jkms.2012.27.5.506

M3 - Article

VL - 27

SP - 506

EP - 511

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 5

ER -